Example: Heart Attack

Search clinical trials for: Cysteamine

Total 29 results

NCT02473445

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Conditions: Mitochondrial Diseases
NCT02212431

Completed

First Study of Oral Cysteamine in Cystic Fibrosis

Conditions: Cystic Fibrosis
NCT02023866

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

Conditions: Inherited Mitochondrial Disease, Including Leigh Syndrome
NCT01529268

Completed

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

Conditions: Nonalcoholic Fatty Liver Disease (NAFLD)
NCT01744782

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Conditions: Cystinosis
NCT01197378

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Conditions: Cystinosis
NCT02012114

Unknown status

A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications

Conditions: Cystinosis
NCT02766855

Completed

Efficacy of Topical Cysteamine in Nephropathic Cyctinosis

Conditions: Nephropathic Cyctinosis; Corneal Cystine Crystals
NCT01432561

Completed

Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™

Conditions: Cystinosis; Nephropathic Cystinosis
NCT03883984

Recruiting

Cysteamine for Asthma

Conditions: Asthma
NCT00715559

Terminated

Cysteamine Therapy for Major Depressive Disorder

Conditions: Major Depressive Disorder
NCT01733316

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Conditions: Cystinosis
NCT01139125

Terminated

An Open Trial of Cysteamine Treatment in Schizophrenia

Conditions: Schizophrenia; Schizoaffective
NCT00001213

Completed

Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis

Conditions: Cystinosis
NCT00872729

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Conditions: Cystinosis
NCT03000348

Completed

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

Conditions: Cystic Fibrosis
NCT01000961

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Conditions: Cystinosis
NCT00001736

Completed

New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis

Conditions: Cystinosis
NCT00799578

Completed

A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

Conditions: Fatty Liver
NCT04246060

Enrolling by invitation

Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients

Conditions: Nephropathic Cystinosis
NCT00002110

Completed

A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease

Conditions: HIV Infections
NCT00028262

Completed

Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis

Conditions: Infantile Neronal Ceroid Lipofuscinosis
NCT00010426

Completed

Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis

Conditions: Cystinosis
NCT02101957

Unknown status

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Conditions: Huntington's Disease
NCT04125927

Not yet recruiting

Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)

Conditions: Cystinosis